Celldex's Barzolvolimab Hits Primary Endpoints in Phase 3 CSU…

Event summary

Celldex's Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials for barzolvolimab met primary and all key secondary endpoints at 12 weeks.
Barzolvolimab demonstrated statistically significant improvements in chronic spontaneous urticaria (CSU) patients refractory to omalizumab.
The treatment was well-tolerated with a favorable safety profile through 24 weeks.
Celldex plans to submit a Biologics License Application (BLA) to the FDA in 2027.

The big picture

Celldex's positive Phase 3 results for barzolvolimab position the drug as a potential best-in-disease treatment for CSU, addressing a significant unmet need in patients refractory to existing therapies. The planned 2027 BLA submission could mark a pivotal shift in the CSU treatment landscape, particularly if barzolvolimab gains approval as a first-line therapy for severe CSU or angioedema. The success of this program also underscores Celldex's growing leadership in mast cell biology, a critical area for inflammatory and autoimmune disorders.

What we're watching

Regulatory Pathway: Whether the FDA will expedite the review process given the strong Phase 3 data.
Market Positioning: How barzolvolimab will differentiate itself in the competitive CSU market, particularly against omalizumab.
Commercialization Strategy: The pace at which Celldex can establish a commercial-stage organization to deliver barzolvolimab to patients.